These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

357 related items for PubMed ID: 30156448

  • 21. Economic burden of major bleeding events in commercially insured patients with von Willebrand disease based on claims data from the United States.
    Lu M, Oladapo A, Wu Y, Farahbakhshian S, Ewenstein B.
    J Manag Care Spec Pharm; 2021 Feb; 27(2):175-185. PubMed ID: 33307935
    [Abstract] [Full Text] [Related]

  • 22. Health care resource utilization and costs among individuals with vs without Huntington disease in a US population.
    To TM, Exuzides A, Abbass IM, Patel AM, Ta JT, Surinach A, Fuller RLM, Luo J.
    J Manag Care Spec Pharm; 2022 Nov; 28(11):1228-1239. PubMed ID: 36282937
    [Abstract] [Full Text] [Related]

  • 23. Health care resource utilization and direct costs incurred over 24 months after initiating galcanezumab or standard-of-care preventive migraine treatments in the United States.
    Varnado OJ, Vu M, Buysman E, Kim G, Allenback G, Hoyt M, Trenz H, Cao F, Viktrup L.
    J Manag Care Spec Pharm; 2024 Aug; 30(8):792-804. PubMed ID: 39088336
    [Abstract] [Full Text] [Related]

  • 24. Persistence with Basal-Bolus Insulin Therapy in Patients with Type 2 Diabetes Mellitus and Effect on Clinical and Economic Outcomes: A Retrospective Claims Database Study.
    Edelman SV, Ermakova A, Xiong Y, Sieradzan R, Taylor SD.
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1420-1431. PubMed ID: 31550190
    [Abstract] [Full Text] [Related]

  • 25. Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy: Findings from a Retrospective US Claims Database Analysis.
    Toro W, Yang M, Georgieva M, Song W, Patel A, Jiang AX, Zhao A, LaMarca N, Dabbous O.
    Adv Ther; 2023 Oct; 40(10):4589-4605. PubMed ID: 37587305
    [Abstract] [Full Text] [Related]

  • 26. Changes in acute headache medication use and health care resource utilization: Results from a randomized, double-blind, placebo-controlled clinical trial evaluating galcanezumab in adults with treatment-resistant migraine (CONQUER).
    Ambrosini A, Estemalik E, Pascual J, Rettiganti M, Stroud C, Day K, Ford J.
    J Manag Care Spec Pharm; 2022 Jun; 28(6):645-656. PubMed ID: 35451858
    [Abstract] [Full Text] [Related]

  • 27. Burden of illness among patients with dementia-related psychosis.
    Frazer M, Abler V, Halpern R, Skoog B, Rashid N.
    J Manag Care Spec Pharm; 2021 Mar; 27(3):367-378. PubMed ID: 33645238
    [Abstract] [Full Text] [Related]

  • 28. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
    Vogelzang NJ, Pal SK, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, Meiselbach MK, Perez JR, Agarwal N.
    J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
    [Abstract] [Full Text] [Related]

  • 29. Economic Impact of Treatment Duration and Persistence with Basal Insulin in Previously Insulin-Naive Users.
    Kalirai S, Duan R, Liu D, Reed BL.
    J Manag Care Spec Pharm; 2017 Mar; 23(3):327-336. PubMed ID: 28230446
    [Abstract] [Full Text] [Related]

  • 30. US health care utilization and costs in adult patients with atopic dermatitis by disease severity.
    Wang X, Boytsov NN, Gorritz M, Malatestinic WN, Goldblum OM, Wade RL.
    J Manag Care Spec Pharm; 2022 Jan; 28(1):69-77. PubMed ID: 34949118
    [Abstract] [Full Text] [Related]

  • 31. Healthcare resource utilization and costs associated with patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive NSCLC in the United States.
    Samuelsen C, Lim J, Golembesky A, Shrestha S, Wang L, Griebsch I.
    J Med Econ; 2020 Jan; 23(1):48-53. PubMed ID: 31314630
    [Abstract] [Full Text] [Related]

  • 32. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
    Doshi JA, Cai Q, Buono JL, Spalding WM, Sarocco P, Tan H, Stephenson JJ, Carson RT.
    J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
    [Abstract] [Full Text] [Related]

  • 33. Patient Outcomes, Health Care Resource Use, and Costs Associated with High Versus Low HEDIS Asthma Medication Ratio.
    Luskin AT, Antonova EN, Broder MS, Chang E, Raimundo K, Solari PG.
    J Manag Care Spec Pharm; 2017 Nov; 23(11):1117-1124. PubMed ID: 29083971
    [Abstract] [Full Text] [Related]

  • 34. Actuarial analysis of private payer administrative claims data for women with endometriosis.
    Mirkin D, Murphy-Barron C, Iwasaki K.
    J Manag Care Pharm; 2007 Apr; 13(3):262-72. PubMed ID: 17407392
    [Abstract] [Full Text] [Related]

  • 35. Patient Characteristics, Health Care Resource Utilization, and Costs Associated with Treatment-Regimen Failure with Biologics in the Treatment of Psoriasis.
    Foster SA, Zhu B, Guo J, Nikai E, Ojeh C, Malatestinic W, Goldblum O, Kornberg LJ, Wu JJ.
    J Manag Care Spec Pharm; 2016 Apr; 22(4):396-405. PubMed ID: 27023693
    [Abstract] [Full Text] [Related]

  • 36. Health care resource use and costs in patients with food allergies: a United States insurance claims database analysis.
    Sindher SB, Warren C, Ciaccio C, Seetasith A, Liu Y, Gupta S, Gupta R.
    J Med Econ; 2024 Apr; 27(1):1027-1035. PubMed ID: 39087236
    [Abstract] [Full Text] [Related]

  • 37. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States.
    Asche CV, Singer ME, Jhaveri M, Chung H, Miller A.
    J Manag Care Pharm; 2010 Apr; 16(9):703-12. PubMed ID: 21067256
    [Abstract] [Full Text] [Related]

  • 38. Burden of illness and costs associated with eosinophilic granulomatosis with polyangiitis: evidence from a managed care database in the United States.
    Bell CF, Blauer-Peterson C, Mao J.
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1249-1259. PubMed ID: 34165321
    [Abstract] [Full Text] [Related]

  • 39. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    Rubin DT, Mittal M, Davis M, Johnson S, Chao J, Skup M.
    J Manag Care Spec Pharm; 2017 Aug; 23(8):859-867. PubMed ID: 28737994
    [Abstract] [Full Text] [Related]

  • 40. The impact of high-risk and chronic opioid use among commercially insured endometriosis patients on health care resource utilization and costs in the United States.
    Estes SJ, Soliman AM, Zivkovic M, Chopra D, Zhu X.
    Womens Health (Lond); 2020 Aug; 16():1745506520965898. PubMed ID: 33357086
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.